Actelion Secures Rights to Nippon Shinyaku’s Hypertension Drug

TOKYO - Switzerland-based biopharma Actelion, has signed a deal this week with Kyoto-based pharma Nippon Shinyaku Co. to license the Japanese company's prostaglandin I-2 receptor agonist NS-304, designed to treat pulmonary arterial hypertension